Integrating network pharmacology and in vivo validation, we reveal that PM suppresses colitis by concurrently inhibiting PI3K-AKT, JAK-STAT, and HIF-1 signaling pathways—key drivers of inflammation and oxidative stress. The gene discussed is AKT1; the disease is colitis.